We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002141 | DOI Listing |
Publication Analysis
Top Keywords
brca2 mutation
8
mutation poor
4
poor response
4
response 177lu-psma
4
therapy
4
177lu-psma therapy
4
therapy case
4
case 66-year-old
4
66-year-old man
4
man castration-resistant
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!